Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Romania to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The market for these drugs has been growing steadily in recent years, driven by various factors.
Customer preferences: Romanian customers prefer bronchodilator drugs that are effective, affordable, and easily accessible. They also tend to prefer drugs that have fewer side effects and can be taken orally rather than through inhalation. However, the preference for oral medication is changing due to the growing popularity of inhalers and nebulizers.
Trends in the market: One of the key trends in the bronchodilator drugs market in Romania is the increasing prevalence of respiratory diseases. This is due to various factors such as air pollution, smoking, and lifestyle changes. As a result, there is a growing demand for bronchodilator drugs to manage these conditions.Another trend in the market is the growing popularity of combination therapies. Many bronchodilator drugs are now being combined with other medications to provide more comprehensive treatment for respiratory diseases. This is particularly true for COPD, which requires a combination of bronchodilators and anti-inflammatory drugs.
Local special circumstances: Romania has a high prevalence of respiratory diseases, which is partly due to its geographical location. The country is located in an area where air pollution is high, and this has contributed to the high incidence of respiratory diseases. Additionally, smoking is still quite prevalent in Romania, which further exacerbates the problem.
Underlying macroeconomic factors: The Romanian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has helped to drive the growth of the bronchodilator drugs market as more people are able to afford these medications. Additionally, the government has been investing in healthcare infrastructure, which has improved access to healthcare services across the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
